GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited. Across 60 ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

Whether they’re using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health. About 1 in 8 U.S. adults say they are taking a GLP-1 drug ...

A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major ...

Studies show tirzepatide leads to significantly more weight loss on average compared to semaglutide. Tirzepatide and semaglutide are both FDA-approved weekly injections for weight management and type ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of metabolic conditions such as obesity and diabetes. In addition to their weight loss benefits, these drugs also ...

Moderate- to high-quality evidence from an umbrella review on non-cardiometabolic outcomes reinforced links between GLP-1 therapies and risks of nausea, vomiting, and diarrhea. High-quality evidence ...

Wegovy was linked to dozens of cases of "eye stroke" in patients from 2021-2024. The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA ...